Richard Feldman
Family Medicine · Indianapolis, INNPI 1134102239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $356,624 of the $475,791 with a category attached, or 75.0%. GSK accounts for 92.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $138,274 and has fallen 99.9% since, to $88 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 603 payments — averaging $789.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$440K
- Sanofi Pasteur Inc.$34K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$205
- Otsuka America Pharmaceutical, Inc.$92
- Boehringer Ingelheim$59
- plus $205 from 9 others
What the payments were for
- Consulting fees$3,1531%
- Speaking & faculty fees$356,62475%
- Travel & lodging$104,04422%
- Food & beverage$11,9703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 501 | $440,402 |
| Sanofi Pasteur Inc. | 69 | $33,539 |
| Biohaven Pharmaceuticals, Inc. | 4 | $1,289 |
| AbbVie | 10 | $205 |
| Otsuka America Pharmaceutical, Inc. | 1 | $92 |
| Boehringer Ingelheim | 5 | $59 |
| Pfizer | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Cranial Technologies, Inc | 1 | $25 |
| Gilead | 2 | $24 |
| Novo Nordisk | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$376,756
- AREXVY$56,577
- FLUZONE HIGH-DOSE$29,040
- FLUBLOK QUADRIVALENT$15,069
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$7,196
- MENQUADFI$2,818
- NURTEC ODT$1,200
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$355
How this compares
$475,791 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 15 | $268 |
| Atorvastatin Calcium | 30 | $214 |
| Amlodipine Besylate | 24 | $188 |
| Alprazolam XrAlprazolam | 11 | $124 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 16 | $77 |
| Losartan Potassium | 12 | $56 |
| Sertraline Hcl | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Indianapolis
- Richard TannerIndianapolis$1.6M
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Blair BrengleIndianapolis$17K
- James AndryBloomington$715K
- Anthony InzerelloEvansville$308K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.